In this edition, combination extends survival vs. standard first-line therapy, integrated care for smoking cessation during lung cancer screening and more. Read the full coverage here: Combination extends survival vs. standard first-line therapy for advanced lung cancer Integrated care 'best treatment option' for smoking cessation during lung cancer screening FDA proposes cap on nicotine levels in cigarettes Global lifetime risk for lung cancer in 2022 differs by human development index, sex FDA grants priority review to oral non-small cell lung cancer drug References: Cinciripini P, et al. JAMA Intern Med. 2024;doi:10.1001/jamainternmed.2024.7288. Li M, et al. Chin Med J (Engl). 2024;doi:10.1097/CM9.0000000000003368. Press Release Press Release Press Release

Ver todos los episodios